Patients after TIA or Stroke are at high risk of experiencing a new stroke or myocardial infarction. Poor adherence to evidence based secondary prevention regimens is frequently seen. Support programs for patients may not only improve adherence to recommended therapies but also reduce the recurrence rate of stroke and heart attack. The investigators hypothesize that compared to regular care, a structured and patient centered secondary prevention program will lead to a relative risk reduction of at least 28% of recurrent vascular events.
Although effective methods of secondary prevention after stroke or TIA are available, adherence to recommended evidence-based treatments is often poor. Programs for supported secondary prevention after cerebrovascular events with improved health education are promising but have not been evaluated regarding recurrent event reduction so far. A prospective randomized trial has been started to assess the effectiveness of a patient centered structured support program intending a reduction of recurrent vascular events. Usual care consists of structured information given at discharge as well as regular outpatient care by general practitioners. The support program additionally employs a stepwise intensified support program with up to eight appointments over two years in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. They are also offered assistance in finding appropriate physical activities or smoking cessation programs. Patients are randomized to regular care or regular care plus support program and will be followed-up until the total number of 317 primary endpoints has been reached. The composite primary endpoint consists of stroke, major coronary event and vascular death.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
2,082
Behavioural: Structured support program Program with up to 8 outpatient appointments focusing on: * Measurement of risk factors * Assessment of medication intake * Monitoring of antithrombotic therapy * Joint agreement of an individual target plan Target values for risk factors: * Blood pressure \< 140/85 mmHg (\<130/80 in diabetics), normal circadian profile * HbA1c \<7.5% * Nicotine abstinence * LDL \< 100mg/dl (\< 70mg/dl in high risk patients) * Physical activity ≥ 30min \>2 x / week Targets for pharmaceutical treatment: * Platelet inhibitors for strokes / TIA of arterial etiology * Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis * Cumarins (INR 2-3) or new oral anticoagulants in AF patients * Statin treatment in patients with LDL \>100mg/dl Intervention strategies: • According to Motivational Interviewing
Dept. of Neurology, Charité Universitätsmedizin Berlin
Berlin, Germany
Major vascular event consisting of nonfatal stroke, nonfatal major coronary event and vascular death
Stroke: Acute (focal-) neurological syndrome, caused by brain infarction or intracerebral hemorrhage Major coronary event:Including instable Angina pectoris, STEMI and non-STEMI Vascular death: Caused by stroke (within 30 days of event), or major coronary event (within 7 days of event), or non-cerebral hemorrhage, or by peripheral arterial disease 30 days after vascular event or vascular intervention (intraarterial or surgical), or by pulmonary embolism or sudden death if death occurs within 24 hours in a patients with previously stable and healthy state if no non-vascular cause is documented
Time frame: Up to 6 years from inclusion
Non vascular death
Time frame: Participants will be followed-up for an average of approximately 3.5 years
Other vascular diseases leading to hospital admission (excl. primary outcome measure)
Consisting of TIA, Angina pectoris, PAD with vascular intervention
Time frame: Participants will be followed-up for an average of approximately 3.5 years
All hospital admissions with vascular intervention (intraarterial or surgical)
Time frame: Participants will be followed-up for an average of approximately 3.5 years
Bleedings
All bleedings leading to therapeutic intervention (categorized according to GUSTO definitions)
Time frame: Participants will be followed-up for an average of approximately 3.5 years
Level of dependency
Assessment according to modified Rankin Score and level of care (German care insurance)
Time frame: Up to 6 years from inclusion
All hospital admissions
Time frame: Participants will be followed-up for an average of approximately 3.5 years
Days alive and at home
Time frame: Participants will be followed-up for an average of approximately 3.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.